DIANA Biotechnologies

DIANA Biotechnologies is a Czech biotechnology company founded in 2018 as an academic spin-off based on the proprietary DIANA technology, invented by Václav Navrátil during his PhD studies. The company is headquartered in Vestec, Czech Republic, and operates as a private entity supported by 3.5 million EUR of private investment. It focuses on four main segments: molecular biology reagents for life science and diagnostic labs, monoclonal antibody development, ultrasensitive sepsis diagnostics, and drug discovery services. The company gained prominence as the largest producer of COVID-19 tests in Czechia, delivering over 6 million PCR tests. This expertise in PCR and RT-PCR technologies has enabled DIANA to build a robust portfolio of PCR and RT-PCR mixes, unique enzymes, and RNase inhibitors. Its DIANA-Ab technology allows the development of monoclonal antibodies with unprecedented affinity and selectivity, even against small molecules. In diagnostics, DIANA offers an ultrasensitive PCR-based sepsis solution that provides results in less than 2 hours. For drug discovery, it provides kinase inhibitor profiling panels covering over 230 known kinases. DIANA Biotechnologies sells its products directly and through a network of distributors across Europe, including BioTech in Czechia, Slovakia, and Hungary; Caltag in the UK and Ireland; VitaSan Labs in Italy; Hoelzel in Germany, Switzerland, and Austria; Techtum Labs in Northern Europe; and Isogen Life Science in Benelux, Spain, and Portugal. The company is led by co-CEOs Václav Navrátil and Martin Dienstbier, with Jiří Schimer as Head of Chemistry and Jan Tykvart as Head of Development. All products are manufactured in-house.

DIANA Biotechnologies was founded in 2018 as an academic spin-off based on the DIANA technology, which was invented by Václav Navrátil during his PhD studies. The technology can be used in diagnostic or academic labs as an ultrasensitive option for detecting pathogens or proteins. The company was established on a strong co-operation of scientists across fields and supported with 3.5 million EUR of private investment. During the COVID-19 pandemic, DIANA Biotechnologies became the largest producer of COVID-19 tests in Czechia, delivering over 6 million PCR tests. This experience allowed the company to build a robust and broad portfolio of PCR and RT-PCR mixes, unique enzymes, and RNase inhibitors. From the development of COVID tests, DIANA evolved into a diversified biotech company. It now provides a wide range of PCR products to diagnostic and academic labs, along with custom oligonucleotide synthesis. Using the DIANA technology, the company develops monoclonal antibodies efficiently and sensitively, and offers drug discovery services including its proprietary DIANA CDK panel. All products are manufactured in-house. The company has expanded its commercial reach through a network of distributors across Europe, covering major markets such as Czechia, Slovakia, Hungary, the UK, Ireland, Italy, Germany, Switzerland, Austria, Northern Europe, Benelux, Spain, and Portugal.

• 2023

  Established distributor network across Europe.

• 2022

  Launched ultrasensitive sepsis diagnostics and kinase inhibitor profiling services.

• 2021

  Expanded product portfolio to include PCR and RT-PCR mixes, enzymes, and RNase inhibitors.

• 2020

  Became the largest producer of COVID-19 tests in Czechia, delivering over 6 million PCR tests.

• 2018

  Founded as an academic spin-off based on the DIANA technology.

Research-driven biotech providing innovative PCR and RT-PCR products, custom oligonucleotide synthesis, monoclonal antibody development, and kinase inhibitor profiling services for global markets.

• DBscript 2.0 and Turbo

  Next-generation reverse transcriptases.

• DB Ultima H

  100% RNA protection even where standard inhibitors fail.

• DIANA Sepsis Diagnostics

  Ultrasensitive PCR-based sepsis solution with results in less than 2 hours.

• DIANA Kinase Inhibitor Profiling

  Service covering over 230 known kinases.

• Custom Oligonucleotide Synthesis

  Custom synthesis of oligonucleotides.

• Monoclonal Antibodies

  Developed using DIANA-Ab technology with high affinity and selectivity.

1. 1DIANA Biotechnologies | Diversified Biotechdianabiotech.com
2. 2DIANA Biotechnologies | Aboutdianabiotech.com
3. 3DIANA Biotechnologies | Molecular reagents for academic labsdianabiotech.com
4. 4DIANA Biotechnologies | Distributorsdianabiotech.com
5. 5Diana Biotechnologies - Wikidatawikidata.org